Nuvilex Could Help Shape Future of Medical Marijuana

On the heels of the latest Barron's cover story, marijuana use is a topic that will continue to gain fans and ultimately approval.

Read more...
 
NORX: An Overlooked Bakken Play
This undiscovered Bakken play could be hugely profitable next year and double from current prices.
Read more...
 
Powerball Winner Could Benefit from INSCOR’s FIT Plan

While the benefits of FIT OPEB to municipalities have taken center stage, the FIT plan for wealthy and uber-wealthy individuals could be a meaningful profit center for INSCOR

Read more...
 
Plandai Could Revolutionize Malaria Treatment

The Company is successful in developing a treatment or preventive vehicle for malaria, it could be a very profitable game-changer for the Company given its South Africa plantation and botanical-based therapeutic and go a long way toward cost-effectively eliminating one of the world’s most severe health issues.

Read more...
 
Nuvilex Could Target Breast Cancer in Future Clinical Trial
Nuvilex Inc. (OTCQB – NVLX) could be viewed as a two-headed oncology treatment entity, rather than a firm with a single, proven oncology indication in its arsenal.
Read more...
 
PLPL: An Under-the-Radar Force in Biotechnology
Plandai Biotechnology develops rich highly bioavailable extracts to treat diseases and medical conditions
Read more...
 
NVLX: Further Due Diligence Prompts Higher Target Price

There are 3 reasons why our price target had to be increased by 40% and could be raised even higher in the coming months. 1.New value for breast cancer indication 2.Nanomedicine getting major dollars 3.Firm gearing up for future trials

Read more...
 
Nanomedicine Activity is Major Positive for NVLX

In recent months, a slew of activity has occurred in the nanomedicine, or nanobiotechnology industry, which bodes well for Nuvilex Inc. (OTCQB – NVLX), an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients. 

Read more...
 
Nuvilex Leverages Disparate Expertise to Develop Cannabis-Focused Cancer Treatment

It is not often that a Company that has expertise in two distinct arenas can combine these two disparate groups to develop what could emerge as a unique and ground-breaking cancer treatment method.

Read more...
 
A Cash Generation Machine
For all of you investors out there, we have also published an update on FAB Universal (FU-NYSE). The Company is kicking butt and taking names. Why don’t you own the stock? It has generated $15M in cash and $0.26 in EPS in the last 2 quarters alone, and has a subsidiary that could be worth $7.00 per share on its own down the road. Not bad for a $4 stock, right?
Read more...
 
<< Start < Prev 31 32 33 34 35 36 37 38 39 Next > End >>

Page 31 of 39